Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

1(17%)

Results Posted

100%(5 trials)

Phase Distribution

Ph phase_1

17%

Ph phase_2

83%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

5(83.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Detailed Status

Completed5

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (16.7%)

Phase 25 (83.3%)

Trials by Status

active_not_recruiting117%

completed583%

Recent Activity

1 active trials

Showing 5 of 6

completedphase_2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

NCT06031844

completedphase_2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

NCT06097663

completedphase_2

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

NCT04886258

active_not_recruitingphase_1

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469

completedphase_2

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

NCT04868968

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT06031844Phase 2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Completed

NCT06097663Phase 2

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Completed

NCT04886258Phase 2

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

Completed

NCT05552469Phase 1

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Active Not Recruiting

NCT04868968Phase 2

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

Completed

NCT04382053Phase 2

Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia